These mechanisms are likely inherent in the phenotype of the particular cancer and some of them can potentiate the effect of mutated BRAF. Hopefully, better insights into these mechanisms may provide clues for developing novel therapeutic strategies for advanced mCRC. The gene discussed is BRAF; the disease is cancer.